SCHEMBL374592

SCHEMBL374592

Cc1[c]ccc(-c2ccccc2C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.45
HTR7 P34969 3/20 0.42
TRPA1 O75762 1/20 0.40
CTSD P07339 1/20 0.40
BACE1 P56817 1/20 0.40
CA12 O43570 2/20 0.40
CA9 Q16790 2/20 0.40
GRIA1 P42261 1/20 0.38
CACNG8 Q8WXS5 1/20 0.38
HTR1A P08908 1/20 0.38
LCK P06239 1/20 0.38
KDR P35968 1/20 0.38
JAK3 P52333 1/20 0.38
MAPK14 Q16539 1/20 0.38
AR P10275 1/20 0.38
PDK2 Q15119 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
NR1H4 Q96RI1 1/20 0.37
EDNRB P24530 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10595614 0.81 MCL1 (0.42) MCL1HTR7TRPA1CTSDBACE1
SCHEMBL15638352 0.81 MCL1 (0.42) MCL1HTR7TRPA1CTSDBACE1
SCHEMBL8125021 0.81 MCL1 (0.42) MCL1HTR7TRPA1CTSDBACE1
SCHEMBL2015544 0.81 PTPRC (0.43) TRPA1BACE1PDK2NPC1RAB9A
SCHEMBL15636889 0.81 CYP2A6 (0.47) TRPA1BACE1JAK3ARPDK2
SCHEMBL4429993 0.78 S1PR4 (0.38) BACE1CYP1A2ALDH1A1CASP3RAB9A
SCHEMBL9545924 0.78 HTR7 (0.41) MCL1HTR7TRPA1CTSDBACE1
SCHEMBL4608554 0.78 PTPRC (0.49) HTR7CA12CA9ARPDK2
SCHEMBL3904470 0.78 MCL1 (0.41) MCL1HTR7TRPA1CTSDBACE1
SCHEMBL2254178 0.78 MCL1 (0.45) MCL1CA12CA9CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240122065-A1 METAL PATTERNING MATERIAL, AMINE COMPOUND, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN TOSOH CORPORATION (JP) 2024-04-11 US disclosed
EP-4342883-A1 PHOTOELECTRIC CONVERSION ELEMENT MATERIAL FOR IMAGING ELEMENT AND PHOTOELECTRIC CONVERSION ELEMENT FOR IMAGING ELEMENT Tosoh Corporation (JP) 2024-03-27 EP disclosed
CN-117440940-A Material for photoelectric conversion element for image pickup element and photoelectric conversion element for image pickup element 东曹株式会社 2024-01-23 CN disclosed
CN-110997648-B Condensed ring compound 东曹株式会社 2023-12-19 CN disclosed
CN-117044428-A Lateral current suppressing material, carbazole compound, hole injection layer, and organic electroluminescent element 东曹株式会社 2023-11-10 CN disclosed
EP-4198163-A1 METAL PATTERNING MATERIAL, AMINE COMPOUND, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN Tosoh Corporation (JP) 2023-06-21 EP disclosed
WO-2023013615-A1 AMINE COMPOUND, HOLE INJECTION LAYER AND ORGANIC ELECTROLUMINESCENT ELEMENT 東ソー株式会社 2023-02-09 WO disclosed
WO-2023013697-A1 MATERIAL FOR METAL PATTERNING, FLUORO COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENCE DEVICE, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN 東ソー株式会社 2023-02-09 WO disclosed
WO-2022260096-A1 PHOTOELECTRIC CONVERSION ELEMENT MATERIAL FOR IMAGING ELEMENT AND PHOTOELECTRIC CONVERSION ELEMENT FOR IMAGING ELEMENT 東ソー株式会社 2022-12-15 WO disclosed
EP-3607002-A1 COLORANT MIXTURES Huntsman Advanced Materials (Switzerland) GmbH (CH) 2020-02-12 EP disclosed
EP-1651614-B1 METHOD FOR THE PRODUCTION OF PURIFIED 1,3-SUBSTITUTED IMIDAZOLIUM SALTS BASF AG (DE) 2007-07-11 EP disclosed
EP-1740171-A1 INDOL-1-YL-ACETIC ACID DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2007-01-10 EP disclosed
US-20060149074-A1 Method for the production of purified 1,3-substituted imidazolium salts BASF AKTIENGESELLSCHAFT (DE) 2006-07-06 US disclosed
US-7053244-B2 Method for the continuous production of tetra-substituted ureas BASF AKTIENGESELLSCHAFT (DE) 2006-05-30 US disclosed
EP-1651614-A1 METHOD FOR THE PRODUCTION OF PURIFIED 1,3-SUBSTITUTED IMIDAZOLIUM SALTS BASF AKTIENGESELLSCHAFT (DE) 2006-05-03 EP disclosed
US-20050261524-A1 Method for the continuous production of tetra-substituted ureas BASF AKTIENGESELLSCHAFT (DE) 2005-11-24 US disclosed
WO-2005094816-A1 INDOL-1-YL-ACETIC ACID DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2005-10-13 WO disclosed
WO-2005019183-A1 METHOD FOR THE PRODUCTION OF PURIFIED 1,3-SUBSTITUTED IMIDAZOLIUM SALTS BASF AKTIENGESELLSCHAFT (DE) 2005-03-03 WO disclosed
EP-1028945-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS Amgen Inc. (US) 2000-08-23 EP disclosed
WO-1999024404-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060149074-A1 Method for the production of purified 1,3-substituted imidazolium salts HIRA, HAO2, HACL2 MCL1 3066/4885HTR7 1005/4885TRPA1 1077/4885
US-20050261524-A1 Method for the continuous production of tetra-substituted ureas UGP2, UTS2R, UMPS MCL1 4183/4885HTR7 1803/4885TRPA1 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.